Targeting angiogenesis in oncology, ophthalmology and beyond

[1]  N. Ferrara,et al.  Endothelial Cell Diversity: the Many Facets of the Crystal. , 2022, The FEBS Journal.

[2]  R. Jain,et al.  Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  J. Kirkland,et al.  Cellular senescence and senolytics: the path to the clinic , 2022, Nature Medicine.

[4]  N. Vale,et al.  Dostarlimab: A Review , 2022, Biomolecules.

[5]  C. Zheng,et al.  Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies , 2022, Frontiers in Oncology.

[6]  K. Thiel,et al.  TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Sadda,et al.  Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options , 2022, Clinical ophthalmology.

[8]  F. Asmus,et al.  INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA , 2022, Retina.

[9]  H. Lenz,et al.  Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer , 2022, JAMA network open.

[10]  Saerom Kim,et al.  Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis® (Ranibizumab) Biosimilar , 2022, Ophthalmology and Therapy.

[11]  Arthur D. Fu,et al.  Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. , 2022, Lancet.

[12]  Jordan M. Graff,et al.  Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials , 2022, The Lancet.

[13]  H. Augustin,et al.  Antiangiogenesis: Vessel Regression, Vessel Normalization, or Both? , 2022, Cancer Research.

[14]  J. Meyerhardt,et al.  Plasma protein markers in advanced or metastatic colorectal cancer patients receiving chemotherapy with bevacizumab or cetuximab: Results from CALGB 80405 (Alliance). , 2021, Clinical Cancer Research.

[15]  L. Antonuzzo,et al.  FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial , 2021, Frontiers in Oncology.

[16]  R. Goldberg,et al.  Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study , 2021, Translational Vision Science & Technology.

[17]  P. Kaiser,et al.  Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration , 2021, JAMA ophthalmology.

[18]  Ruikang K. Wang,et al.  LIF, a mitogen for choroidal endothelial cells, protects the choriocapillaris: implications for prevention of geographic atrophy , 2021, EMBO molecular medicine.

[19]  E. Schmidt,et al.  354 Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study , 2021, Journal for ImmunoTherapy of Cancer.

[20]  E. Deeks.  Belzutifan: First Approval , 2021, Drugs.

[21]  P. Kaiser,et al.  Pipeline therapies for neovascular age related macular degeneration , 2021, International Journal of Retina and Vitreous.

[22]  P. Campochiaro,et al.  Archway Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration. , 2021, Ophthalmology.

[23]  A. Oza,et al.  A Long‐Term Extension Study of Bevacizumab in Patients With Solid Tumors , 2021, The oncologist.

[24]  G. Coukos,et al.  VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding , 2021, Journal for ImmunoTherapy of Cancer.

[25]  M. Socinski,et al.  IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  A. Berrocal,et al.  Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration , 2021, Drug design, development and therapy.

[27]  Florence T. H. Wu,et al.  Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer , 2021, EMBO molecular medicine.

[28]  H. Harada,et al.  An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor , 2021, Cancers.

[29]  R. Gallemore,et al.  Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options , 2021, Cells.

[30]  M. Brzozowa-Zasada.  The role of Notch ligand, Delta-like ligand 4 (DLL4), in cancer angiogenesis—implications for therapy , 2021, European Surgery.

[31]  E. Jonasch,et al.  Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis , 2021, Nature Medicine.

[32]  Pallavi Sharma,et al.  Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema , 2021, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[33]  Baolin Zhang,et al.  Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics , 2021, The AAPS Journal.

[34]  J. Hainsworth,et al.  Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma , 2021, Clinical Cancer Research.

[35]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[36]  Frédérick A. Mallette,et al.  Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition. , 2021, Cell metabolism.

[37]  C. Traverso,et al.  Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases , 2021, Expert opinion on investigational drugs.

[38]  V. Madanagopalan,et al.  KSI-301: antibody biopolymer conjugate in retinal disorders , 2021, Therapeutic advances in ophthalmology.

[39]  B. Fu,et al.  Resistance Mechanisms of Anti-angiogenic Therapy and Exosomes-Mediated Revascularization in Cancer , 2020, Frontiers in Cell and Developmental Biology.

[40]  H. Xin,et al.  Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways , 2020, Nature Communications.

[41]  K. Denhaerynck,et al.  Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study) , 2020, Clinical ophthalmology.

[42]  Yulei N. Wang,et al.  Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities , 2020, Frontiers in Immunology.

[43]  W. Nickel,et al.  FGF2 and IL-1β – explorers of unconventional secretory pathways at a glance , 2020, Journal of Cell Science.

[44]  Q. Nguyen,et al.  The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye , 2020, International Journal of Retina and Vitreous.

[45]  B. Escudier,et al.  TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients with Metastatic Renal Cell Carcinoma. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  W. Lee,et al.  Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity , 2020, Experimental & Molecular Medicine.

[47]  P. Hegde,et al.  Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer , 2020, Proceedings of the National Academy of Sciences.

[48]  R. Muschel,et al.  FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy , 2020, Nature Communications.

[49]  P. Mitchell,et al.  Anti-vascular endothelial growth factor in neovascular age-related macular degeneration – a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems , 2020, BMC Ophthalmology.

[50]  Junnian Zheng,et al.  Turning Cold into Hot: Firing up the Tumor Microenvironment. , 2020, Trends in cancer.

[51]  P. Rosenfeld,et al.  APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration , 2020, British Journal of Ophthalmology.

[52]  R. Langer,et al.  Parallel evolution of polymer chemistry and immunology: Integrating mechanistic biology with materials design. , 2020, Advanced drug delivery reviews.

[53]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[54]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[55]  G. Virgili,et al.  Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. , 2020, The Cochrane database of systematic reviews.

[56]  S. Hariprasad,et al.  Risuteganib—a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema , 2020, Expert opinion on investigational drugs.

[57]  Shadi Toghi Eshghi,et al.  Development of a therapeutic anti-HtrA1 antibody and the identification of DKK3 as a pharmacodynamic biomarker in geographic atrophy , 2020, Proceedings of the National Academy of Sciences.

[58]  A. Ravaud,et al.  Patient‐reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma , 2020, BJU international.

[59]  O. Chinot,et al.  Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. , 2020, Cancer treatment reviews.

[60]  D. Mukherji,et al.  Resistance Mechanisms to Anti-angiogenic Therapies in Cancer , 2020, Frontiers in Oncology.

[61]  R. Jain,et al.  Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges , 2020, Nature Reviews Clinical Oncology.

[62]  R. Burger,et al.  Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218 , 2020, Clinical Cancer Research.

[63]  H. Hurwitz,et al.  The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC) , 2019, The oncologist.

[64]  Qingyun Zhou,et al.  One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema , 2019, Molecular vision.

[65]  A. Griffioen,et al.  The tumor vasculature an attractive CAR T cell target in solid tumors , 2019, Angiogenesis.

[66]  P. Mitchell,et al.  Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy – a systematic approach to identify and characterize data sources , 2019, BMC Ophthalmology.

[67]  A. Loewenstein,et al.  Abicipar pegol—a novel anti-VEGF therapy with a long duration of action , 2019, Eye.

[68]  G. Liew,et al.  Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients , 2019, Vision.

[69]  Yihai Cao.  Adipocyte and lipid metabolism in cancer drug resistance. , 2019, The Journal of clinical investigation.

[70]  K. Bensalah,et al.  Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. , 2019, European urology.

[71]  A. Loewenstein,et al.  Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies. , 2019, Ophthalmology. Retina.

[72]  C. Porta,et al.  Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial , 2019, The Lancet.

[73]  S. Park,et al.  High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer , 2019, Journal of Cancer.

[74]  Alan W. Stitt,et al.  The Placental Growth Factor Pathway and Its Potential Role in Macular Degenerative Disease , 2019, Current eye research.

[75]  N. Ferrara,et al.  VEGF in Signaling and Disease: Beyond Discovery and Development , 2019, Cell.

[76]  Ahmed E. Radwan,et al.  Long‐acting intraocular Delivery strategies for biological therapy of age‐related macular degeneration , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[77]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[78]  G. Gao,et al.  Adeno-associated virus vector as a platform for gene therapy delivery , 2019, Nature Reviews Drug Discovery.

[79]  M. Kudo,et al.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[80]  U. Schmidt-Erfurth,et al.  HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. , 2019, Ophthalmology.

[81]  Jeffrey Heier,et al.  Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16. , 2018, Ophthalmology.

[82]  M. Odenthal,et al.  Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. , 2018, Cancer research.

[83]  Gisela Schwab,et al.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.

[84]  Yihai Cao,et al.  Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance. , 2018, Cell metabolism.

[85]  Y. Sakai,et al.  Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway , 2018, International journal of molecular sciences.

[86]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[87]  J. Duyster,et al.  Anti-Angiogenics: Current Situation and Future Perspectives , 2018, Oncology Research and Treatment.

[88]  R. Kerbel,et al.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa , 2018, Nature Reviews Clinical Oncology.

[89]  Yihai Cao,et al.  Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning , 2018, The Journal of experimental medicine.

[90]  Eric M. Moult,et al.  Choriocapillaris Loss in Advanced Age-Related Macular Degeneration , 2018, Journal of ophthalmology.

[91]  P. Campochiaro,et al.  AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[92]  P. Carmeliet,et al.  Endothelial Cell Metabolism. , 2018, Physiological reviews.

[93]  N. Samani,et al.  A miR-327–FGF10–FGFR2-mediated autocrine signaling mechanism controls white fat browning , 2017, Nature Communications.

[94]  R. Burger,et al.  Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses , 2017, Journal of the National Cancer Institute.

[95]  H. Augustin,et al.  Organotypic vasculature: From descriptive heterogeneity to functional pathophysiology , 2017, Science.

[96]  Yihai Cao,et al.  Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy , 2017, Proceedings of the National Academy of Sciences.

[97]  A Lotery,et al.  Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial , 2017, The Lancet.

[98]  K. Alitalo,et al.  Therapeutic targeting of the angiopoietin–TIE pathway , 2017, Nature Reviews Drug Discovery.

[99]  S. Ylä-Herttuala,et al.  Angiogenic gene therapy in cardiovascular diseases: dream or vision? , 2017, European heart journal.

[100]  J. Figueira,et al.  Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy , 2017, Journal of ophthalmology.

[101]  N. Samani,et al.  Switching harmful visceral fat to beneficial energy combustion improves metabolic dysfunctions , 2017, JCI insight.

[102]  V. Sheth,et al.  An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. , 2017, Ophthalmic surgery, lasers & imaging retina.

[103]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[104]  T. Helbich,et al.  Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors , 2017, Theranostics.

[105]  Mark W. Tibbitt,et al.  Living Biomaterials. , 2017, Accounts of chemical research.

[106]  G. G. Van den Eynden,et al.  Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases , 2016, Nature Medicine.

[107]  Ying Cheng,et al.  Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  Yihai Cao,et al.  Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism , 2016, Nature Communications.

[109]  N. Samani,et al.  Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fat , 2016, Nature Communications.

[110]  P. Campochiaro,et al.  Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression. , 2016, Ophthalmology.

[111]  Glenn J Jaffe,et al.  Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. , 2016, Ophthalmology.

[112]  N. Samani,et al.  Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy , 2016, Proceedings of the National Academy of Sciences.

[113]  Napoleone Ferrara,et al.  Ten years of anti-vascular endothelial growth factor therapy , 2016, Nature Reviews Drug Discovery.

[114]  Yara T. E. Lechanteur,et al.  Nature Genetics Advance Online Publication , 2022 .

[115]  J. Larkin,et al.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. , 2015, The Lancet. Oncology.

[116]  P. Campochiaro,et al.  Molecular pathogenesis of retinal and choroidal vascular diseases , 2015, Progress in Retinal and Eye Research.

[117]  P. Kaiser,et al.  Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. , 2015, Ophthalmology.

[118]  S. Harding,et al.  Defining response to anti-VEGF therapies in neovascular AMD , 2015, Eye.

[119]  V. Perez,et al.  Immune mechanisms in inflammatory and degenerative eye disease. , 2015, Trends in immunology.

[120]  E. Van Cutsem,et al.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. , 2015, The Lancet. Oncology.

[121]  Jennifer K. Sun,et al.  Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. , 2015, The New England journal of medicine.

[122]  M. Maguire,et al.  Treatment choice for diabetic macular edema. , 2015, The New England journal of medicine.

[123]  P. Campochiaro,et al.  Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. , 2015, Ophthalmology.

[124]  K. Alitalo,et al.  Endothelial destabilization by angiopoietin-2 via integrin β1 activation , 2015, Nature Communications.

[125]  P. Kaiser,et al.  Intravitreal aflibercept for diabetic macular edema. , 2014, Ophthalmology.

[126]  Branimir Sikic,et al.  A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors , 2014, Clinical Cancer Research.

[127]  N. Samani,et al.  Modulation of age-related insulin sensitivity by VEGF-dependent vascular plasticity in adipose tissues , 2014, Proceedings of the National Academy of Sciences.

[128]  Giovanni Staurenghi,et al.  Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration , 2014, British Journal of Ophthalmology.

[129]  Yihai Cao.  VEGF-targeted cancer therapeutics—paradoxical effects in endocrine organs , 2014, Nature Reviews Endocrinology.

[130]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[131]  I. Keklikoglou,et al.  Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. , 2014, Cell reports.

[132]  R. Paschke,et al.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial , 2014, The Lancet.

[133]  A. Tee,et al.  mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3 , 2014, Oncogene.

[134]  Sabita Roy,et al.  Vascular Endothelial Growth Factor Signaling in Hypoxia and Inflammation , 2014, Journal of Neuroimmune Pharmacology.

[135]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[136]  P. Osaadon,et al.  A review of anti-VEGF agents for proliferative diabetic retinopathy , 2014, Eye.

[137]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[138]  I. Salti,et al.  Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment , 2013, BioMed research international.

[139]  M. Kreissl,et al.  Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  Yihai Cao,et al.  Angiogenesis and vascular functions in modulation of obesity, adipose metabolism, and insulin sensitivity. , 2013, Cell metabolism.

[141]  Q. Nguyen,et al.  Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. , 2013, Ophthalmology.

[142]  Zhaoshi Jiang,et al.  An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy , 2013, Nature Medicine.

[143]  Baocun Sun,et al.  Anti-VEGF– and anti-VEGF receptor–induced vascular alteration in mouse healthy tissues , 2013, Proceedings of the National Academy of Sciences.

[144]  G. Pagès,et al.  Mechanisms of resistance to anti-angiogenesis therapies. , 2013, Biochimie.

[145]  H. Yoshiji,et al.  Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti‐tumour effect in vivo , 2013, Clinical and experimental immunology.

[146]  R. Motzer,et al.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[147]  F. Peale,et al.  Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF–induced neutrophil recruitment , 2013, Proceedings of the National Academy of Sciences.

[148]  J. Campisi.  Aging, cellular senescence, and cancer. , 2013, Annual review of physiology.

[149]  S. Bates,et al.  Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma , 2013, Cell reports.

[150]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[151]  J. Blay,et al.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[152]  T. Pawson,et al.  Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. , 2013, Cell metabolism.

[153]  Y. Ogura,et al.  VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study , 2013, British Journal of Ophthalmology.

[154]  H. Hurwitz,et al.  Ziv-aflibercept: binding to more than VEGF-A--does more matter? , 2013, Nature reviews. Clinical oncology.

[155]  M. Shibuya,et al.  Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs , 2012, Proceedings of the National Academy of Sciences.

[156]  Christian Simader,et al.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.

[157]  P. Hegde,et al.  Predictive Impact of Circulating Vascular Endothelial Growth Factor in 4 Phase Iii Trials Evaluating Bevacizumab Departments of 1 , 2022 .

[158]  N. Bressler,et al.  Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. , 2012, Ophthalmology.

[159]  E. Van Cutsem,et al.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  Lorenzo Deveza,et al.  Therapeutic Angiogenesis for Treating Cardiovascular Diseases , 2012, Theranostics.

[161]  F. Peale,et al.  Differential drug class‐specific metastatic effects following treatment with a panel of angiogenesis inhibitors , 2012, The Journal of pathology.

[162]  I. Kasman,et al.  Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models , 2012, The Journal of pathology.

[163]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[164]  L. Ellis,et al.  Antiangiogenic therapy—evolving view based on clinical trial results , 2012, Nature Reviews Clinical Oncology.

[165]  E. Baudin,et al.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  D. Ingber,et al.  Forty-Year Journey of Angiogenesis Translational Research , 2011, Science Translational Medicine.

[167]  P. Larsen,et al.  Thyroid dysfunction from antineoplastic agents. , 2011, Journal of the National Cancer Institute.

[168]  E. Stone,et al.  Elevated membrane attack complex in human choroid with high risk complement factor H genotypes. , 2011, Experimental eye research.

[169]  Amrita,et al.  Increased expression of multifunctional serine protease, HTRA1, in retinal pigment epithelium induces polypoidal choroidal vasculopathy in mice , 2011, Proceedings of the National Academy of Sciences.

[170]  B. Rini,et al.  MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. , 2011, International immunopharmacology.

[171]  M. Laouri,et al.  The burden of disease of retinal vein occlusion: review of the literature , 2011, Eye.

[172]  K. Plate,et al.  Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion , 2011, The Journal of Immunology.

[173]  Francesco Bandello,et al.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. , 2011, Ophthalmology.

[174]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[175]  E. Van Cutsem,et al.  Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  Yihai Cao.  Off-tumor target—beneficial site for antiangiogenic cancer therapy? , 2010, Nature Reviews Clinical Oncology.

[177]  Napoleone Ferrara,et al.  Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy , 2010, Nature Medicine.

[178]  S. Verma,et al.  Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. , 2010, Current oncology.

[179]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[180]  Thijs J. Hagenbeek,et al.  PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth , 2010, Cell.

[181]  Toshiaki Watanabe,et al.  Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6. , 2010, Oncology Letters.

[182]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[183]  K. Alitalo,et al.  Lymphangiogenesis: Molecular Mechanisms and Future Promise , 2010, Cell.

[184]  Minhong Yan,et al.  Chronic DLL4 blockade induces vascular neoplasms , 2010, Nature.

[185]  Yihai Cao.  Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases , 2010, Nature Reviews Drug Discovery.

[186]  Yihai Cao,et al.  Optimizing the Delivery of Cancer Drugs That Block Angiogenesis , 2010, Science Translational Medicine.

[187]  T. Vogl,et al.  Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.

[188]  Ming-Chih Crouthamel,et al.  Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors , 2009, British Journal of Cancer.

[189]  Yihai Cao,et al.  Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature , 2009, Proceedings of the National Academy of Sciences.

[190]  Y. Meng,et al.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.

[191]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[192]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[193]  M. Mohammadi,et al.  The FGF family: biology, pathophysiology and therapy , 2009, Nature Reviews Drug Discovery.

[194]  Yihai Cao.  Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands , 2009, Science Signaling.

[195]  H. Dvorak,et al.  Why are tumour blood vessels abnormal and why is it important to know? , 2009, British Journal of Cancer.

[196]  Zhen-ping Zhu,et al.  Supplemental Data Hypoxia-Independent Angiogenesis in Adipose Tissues during Cold Acclimation , 2008 .

[197]  Yihai Cao.  Tumor angiogenesis and molecular targets for therapy. , 2009, Frontiers in bioscience.

[198]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[199]  A. Hansen,et al.  Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome , 2008, Proceedings of the National Academy of Sciences.

[200]  R. Hammer,et al.  White Fat Progenitor Cells Reside in the Adipose Vasculature , 2008, Science.

[201]  G. Thurston,et al.  VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis , 2008, British Journal of Cancer.

[202]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[203]  Antonio Duarte,et al.  Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation , 2008, Nature.

[204]  S. Frede,et al.  Imaging of the hypoxia-inducible factor pathway: insights into oxygen sensing , 2008, European Respiratory Journal.

[205]  Jing Xiong.  Molecular and developmental biology of the hemangioblast , 2008, Developmental dynamics : an official publication of the American Association of Anatomists.

[206]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[207]  B. Spiegelman,et al.  HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α , 2008, Nature.

[208]  Mallika Singh,et al.  Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression , 2008, Proceedings of the National Academy of Sciences.

[209]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[210]  F. Ziemssen,et al.  Bevacizumab: Off-label use in ophthalmology , 2007, Indian journal of ophthalmology.

[211]  Yihai Cao,et al.  Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. , 2007, The Journal of clinical investigation.

[212]  Yihai Cao.  Angiogenesis modulates adipogenesis and obesity. , 2007, The Journal of clinical investigation.

[213]  F. Radtke,et al.  Notch and cancer: a double-edged sword , 2007, Cellular and Molecular Life Sciences.

[214]  Yihai Cao,et al.  Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs , 2007, Proceedings of the National Academy of Sciences.

[215]  Victoria Bolós,et al.  Notch signaling in development and cancer. , 2007, Endocrine reviews.

[216]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[217]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[218]  Gavin Thurston,et al.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis , 2006, Nature.

[219]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[220]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[221]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[222]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.

[223]  L. Damico,et al.  DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[224]  R. Motzer,et al.  Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.

[225]  K. Alitalo,et al.  Signaling and Functions of Angiopoietin-1 in Vascular Protection , 2006, Circulation research.

[226]  Ricky T. Tong,et al.  Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. , 2006, Cancer research.

[227]  Betty Y. Y. Tam,et al.  VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. , 2006, American journal of physiology. Heart and circulatory physiology.

[228]  H. Yoshiji,et al.  Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice , 2005, Gut.

[229]  S. Ylä-Herttuala,et al.  Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart--gene therapy. , 2005, Cardiovascular research.

[230]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[231]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[232]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[233]  Yihai Cao,et al.  Angiogenesis Inhibitor, TNP-470, Prevents Diet-Induced and Genetic Obesity in Mice , 2004, Circulation research.

[234]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[235]  G. Semenza.  Intratumoral hypoxia, radiation resistance, and HIF-1. , 2004, Cancer cell.

[236]  F. Peale,et al.  Expression of vascular endothelial growth factor, hypoxia inducible factor 1α, and carbonic anhydrase IX in human tumours , 2004, Journal of Clinical Pathology.

[237]  N. Bressler.  Age-related macular degeneration is the leading cause of blindness... , 2004, JAMA.

[238]  J. Thyberg,et al.  Comparative Evaluation of FGF-2–, VEGF-A–, and VEGF-C–Induced Angiogenesis, Lymphangiogenesis, Vascular Fenestrations, and Permeability , 2004, Circulation research.

[239]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[240]  P. Thorpe.  Vascular Targeting Agents as Cancer Therapeutics , 2004, Clinical Cancer Research.

[241]  J. Foidart,et al.  Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. , 2003, The Journal of clinical endocrinology and metabolism.

[242]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[243]  Gudrun Dandekar,et al.  Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells , 2003, Journal of Cell Science.

[244]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[245]  Philippe Leboulch,et al.  Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.

[246]  Richard A. Lang,et al.  Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[247]  B. Lowell,et al.  Adipose tissue mass can be regulated through the vasculature , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[248]  Yihai Cao,et al.  Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. , 2002, Cancer Cell.

[249]  Yuichi Makino,et al.  Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression , 2001, Nature.

[250]  F. Peale,et al.  Identification of an angiogenic mitogen selective for endocrine gland endothelium , 2001, Nature.

[251]  L. Chin,et al.  Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[252]  T. Sano,et al.  [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[253]  Till Acker,et al.  Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration , 2001, Nature Genetics.

[254]  Asif Ahmed,et al.  Release and Complex Formation of Soluble VEGFR-1 from Endothelial Cells and Biological Fluids , 2000, Laboratory Investigation.

[255]  C. Basilico,et al.  Compensation by Fibroblast Growth Factor 1 (FGF1) Does Not Account for the Mild Phenotypic Defects Observed in FGF2 Null Mice , 2000, Molecular and Cellular Biology.

[256]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[257]  K. Alitalo,et al.  Vascular endothelial growth factor C induces angiogenesis in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[258]  P. Campochiaro,et al.  Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. , 1998, The American journal of pathology.

[259]  P. Campochiaro,et al.  Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. , 1998, The American journal of pathology.

[260]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[261]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[262]  Yihai Cao,et al.  Proteolytic processing regulates receptor specificity and activity of VEGF‐C , 1997, The EMBO journal.

[263]  Joan W. Miller,et al.  Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. , 1996, Ophthalmology.

[264]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[265]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[266]  J. Folkman.  Tumor angiogenesis and tissue factor , 1996, Nature Medicine.

[267]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[268]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[269]  A. Logan,et al.  Angiogenesis , 1993, The Lancet.

[270]  J. Winer,et al.  Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: identification as leukemia inhibitory factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[271]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[272]  D. Connolly,et al.  Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.

[273]  Y. Ueyama,et al.  Sinusoidal dilatation of the liver as a paraneoplastic manifestation of renal cell carcinoma. , 1989, Human pathology.

[274]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[275]  R. Langer,et al.  Polymers for the sustained release of proteins and other macromolecules , 1976, Nature.

[276]  R. Langer,et al.  Isolations of a cartilage factor that inhibits tumor neovascularization. , 1976, Science.

[277]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[278]  Ic. Michaelson,et al.  The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases , 1948 .

[279]  H. W. Chalkley,et al.  Vasculae Reactions of Normal and Malignant Tissues in Vivo. I. Vascular Reactions of Mice to Wounds and to Normal and Neoplastic Transplants , 1945 .